Osvaldo Fridman1, Luis Gariglio2, Stephanie Riviere3, Rafael Porcile2, Alicia Fuchs3, Miguel Potenzoni2. 1. Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS), Universidad Abierta Interamericana (UAI), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. Electronic address: osvaldo.fridman@gmail.com. 2. Hospital Universitario, Universidad Abierta Interamericana (UAI), Buenos Aires, Argentina. 3. Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS), Universidad Abierta Interamericana (UAI), Buenos Aires, Argentina.
Abstract
OBJECTIVES: Oxidative stress and inflammation are important processes in development of atherosclerosis. Paraoxonase 1 (PON1) is a bioscavenger enzyme associated with inflammation and oxidative stress. We evaluate the association of two single nucleotide polymorphisms in PON1 gene, and enzyme activities with lipid profile and glycemia. METHODS: This case-control study consisted of 126 patients with coronary artery disease (CAD) and 203 healthy controls. PON Q192R and L55M polymorphisms were detected by real-time PCR. Paraoxonase and arylesterase activities were determined spectrophotometrically. Blood glucose, cholesterol, triglycerides, HDL, and LDL were measured. RESULTS: PON1 QR192 polymorphism had a major effect on paraoxonase but no effect on arylesterase serum activities. Paraoxonase activity was higher in RR genotype and lowest in QQ genotype. Paraoxonase and arylesterase activities were higher in LL and lower in MM genotypes of PON1 LM55 polymorphism. RQ and LM variants showed intermediate activities between respective homozygous. Elevated concentrations of triglycerides in cases correlate with QQ variant or the presence of M allele. Glucose levels were elevated in cases with QQ variant or with the presence of M allele. Cholesterol and LDL did not show variations in control and cases with any variant of both polymorphisms. HDL is lower in cases with respect to controls independently of genotypes. All differences were significant with p<0.05. CONCLUSIONS: Our results confirm the relationship between variations in PON1 activities and lipid metabolism, and showed that genetically programmed low PON1 activities would have certain responsibility in the increase in glycemia and concomitantly the aggravation of atherosclerotic disease.
OBJECTIVES: Oxidative stress and inflammation are important processes in development of atherosclerosis. Paraoxonase 1 (PON1) is a bioscavenger enzyme associated with inflammation and oxidative stress. We evaluate the association of two single nucleotide polymorphisms in PON1 gene, and enzyme activities with lipid profile and glycemia. METHODS: This case-control study consisted of 126 patients with coronary artery disease (CAD) and 203 healthy controls. PONQ192R and L55M polymorphisms were detected by real-time PCR. Paraoxonase and arylesterase activities were determined spectrophotometrically. Blood glucose, cholesterol, triglycerides, HDL, and LDL were measured. RESULTS:PON1 QR192 polymorphism had a major effect on paraoxonase but no effect on arylesterase serum activities. Paraoxonase activity was higher in RR genotype and lowest in QQ genotype. Paraoxonase and arylesterase activities were higher in LL and lower in MM genotypes of PON1 LM55 polymorphism. RQ and LM variants showed intermediate activities between respective homozygous. Elevated concentrations of triglycerides in cases correlate with QQ variant or the presence of M allele. Glucose levels were elevated in cases with QQ variant or with the presence of M allele. Cholesterol and LDL did not show variations in control and cases with any variant of both polymorphisms. HDL is lower in cases with respect to controls independently of genotypes. All differences were significant with p<0.05. CONCLUSIONS: Our results confirm the relationship between variations in PON1 activities and lipid metabolism, and showed that genetically programmed low PON1 activities would have certain responsibility in the increase in glycemia and concomitantly the aggravation of atherosclerotic disease.
Authors: A A Hernández-Collazo; Oscar Pérez-Méndez; Victoria López-Olmos; V Delgado-Rizo; J F Muñoz-Valle; Erika Martínez-López; D G Villanueva-Quintero; Carolina Domínguez-Díaz; Mary Fafutis-Morris; Anabell Alvarado-Navarro Journal: Mol Biol Rep Date: 2020-12-07 Impact factor: 2.316
Authors: Khalid Khalaf Alharbi; May Salem Alnbaheen; Fawiziah Khalaf Alharbi; Rana M Hasanato; Imran Ali Khan Journal: Ann Saudi Med Date: 2017 Nov-Dec Impact factor: 1.526
Authors: David Corredor-Orlandelli; Santiago Sambracos-Parrado; Santiago Mantilla-García; Josué Tovar-Tirado; Valentina Vega-Ramírez; Santiago David Mendoza-Ayús; Laura Catalina Peña; María Fernanda Leal; Juliana Rodríguez-Carrillo; Juanita León-Torres; Juan Mauricio Pardo-Oviedo; Katherine Parra Abaunza; Nora Contreras Contreras Bravo; Oscar Ortega-Recalde; Dora Janeth Fonseca Mendoza Journal: Vasc Health Risk Manag Date: 2021-11-03
Authors: Khairul Anwar Zarkasi; Nor Azian Abdul Murad; Norfazilah Ahmad; Rahman Jamal; Noraidatulakma Abdullah Journal: Int J Environ Res Public Health Date: 2022-01-06 Impact factor: 3.390